Environmental and genomic factors as well as interventions influencing smoking cessation: A systematic review of reviews and a proposed working model

Public Health Genomics

Volumn 16, Issue 4, 2013, Pages 159-173

  De Viron, S ^a,b,c   Malats, N ^d   Van Der Heyden, J ^a   Van Oyen, H ^a   Brand, A ^b,c  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Environment; Genomics; Intervention; Public health; Public health genomics; Smoking cessation; Systematic review; Working model

Indexed keywords

AMFEBUTAMONE; CLONIDINE; CYTISINE; DOPAMINE; NALTREXONE; NICOTINIC RECEPTOR; NORTRIPTYLINE; OPIATE; SEROTONIN; VARENICLINE;

ACUPUNCTURE; ALCOHOLISM; ALLELE; AVERSION THERAPY; BIOLOGICAL FUNCTIONS; COUNSELING; DEPRESSION; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; META ANALYSIS; MOTIVATIONAL INTERVIEWING; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH PROBLEM; REVIEW; RISK ASSESSMENT; SELF HELP; SMOKING; SMOKING CESSATION; SOCIAL ASPECT; SOCIAL STATUS; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; VARIABLE NUMBER OF TANDEM REPEAT; COCHRANE LIBRARY; DATA EXTRACTION; GENOMICS; MEDLINE;

EID: 84881527664     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000351453     Document Type: Review

References (146)

1. World Health Organization: WHO Report on the global tobacco epidemic, implementing smoke-free environments. Geneva, World Health Organization, 2009.
2. Godtfredsen NS, Osler M, Vestbo J, Andersen I, Prescott E: Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. J Epidemiol Community Health 2003; 57:412.
3. White WB: Smoking-related morbidity and mortality in the cardiovascular setting. Prev Cardiol 2007; 10(2 suppl 1):1-4.
4. Willemse BW, Postma DS, Timens W, ten Hacken NH: The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23:464-476.
5. Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J: Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res Hum Genet 2006; 9:64-72.
6. Kendler KS, Thornton LM, Pedersen NL: Tobacco consumption in Swedish twins reared apart and reared together. Arch Gen Psychiatry 2000; 57:886-892.
7. Du Y, Wan YJ: The interaction of reward genes with environmental factors in contribution to alcoholism in Mexican Americans. Alcohol Clin Exp Res 2009; 33:2103-2112.
8. Plomin R, Defries JC, McClearn GE, McGuf-fin P: Behavioral Genetics. New York, Worth Publishers, 2008.
9. Fong GT, Cummings KM, Borland R, Hastings G, Hyland A, Giovino GA, Hammond D, Thompson ME: The conceptual framework of the International Tobacco Control (ITC) Policy Evaluation Project. Tob Control 2006; 15(suppl 3):iii3-iii11.
10. Manfredi C, Cho YI, Crittenden KS, Dolecek TA: A path model of smoking cessation in women smokers of low socio-economic status. Health Educ Res 2007; 22:747-756.
11. Talikka M, Sierro N, Ivanov NV, Chaudhary N, Peck MJ, Hoeng J, Coggins CR, Peitsch MC: Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit Rev Toxicol 2012; 42:877-889.
12. Centers for Disease Control and Prevention: Cigarette smoking among adults-United States, 2007. MMWMR 2008; 57:1221-1226.
13. Hughes JR, Keely J, Naud S: Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99:29-38.
14. Galea S, Riddle M, Kaplan GA: Causal thinking and complex system approaches in epidemiology. Int J Epidemiol 2010; 39:97-106.
15. Rothman KJ, Greenland S: Causation and causal inference in epidemiology. Am J Public Health 2005; 95(suppl 1):S144-S150.
16. Hovell MF, Hughes SC: The behavioral ecology of secondhand smoke exposure: a pathway to complete tobacco control. Nicotine Tob Res 2009; 11:1254-1264.
17. Honjo K, Tsutsumi A, Kawachi I, Kawakami N: What accounts for the relationship between social class and smoking cessation? Results of a path analysis. Soc Sci Med 2006; 62: 317-328.
18. Lerman CE, Schnoll RA, Munafò MR: Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 2007; 33(suppl 6):S398-S405.
19. Swan GE, Hudmon KS, Jack LM, Hemberger K, Carmelli D, Khroyan TV, Ring HZ, Hops H, Andrews JA, Tildesley E, McBride D, Ben-owitz N, Webster C, Wilhelmsen KC, Feiler HS, Koenig B, Caron L, Illes J, Cheng LS: Environmental and genetic determinants of tobacco use: methodology for a multidisci-plinary, longitudinal family-based investigation. Cancer Epidemiol Biomarkers Prev 2003; 12:994-1005.
20. Race, Ethnicity, and Genetics Working Group: The use of racial, ethnic, and ancestral categories in human genetics research. Am J Hum Genet 2005; 77:519-532.
21. Caponnetto P, Polosa R: Common predictors of smoking cessation in clinical practice. Respir Med 2008; 102:1182-1192.
22. Cengelli S, O'Loughlin J, Lauzon B, Cornuz J: A systematic review of longitudinal population-based studies on the predictors of smoking cessation in adolescent and young adult smokers. Tob Control 2012; 21:355-362.
23. Bader P, Travis HE, Skinner HA: Knowledge synthesis of smoking cessation among employed and unemployed young adults. Am J Public Health 2007; 97:1434-1443.
24. Vangeli E, Stapleton J, Smit ES, Borland R, West R: Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction 2011; 106:2110-2121.
25. Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D: 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technol Assess 2008; 12:iii-xi, 1-135.
26. Cahill K, Lancaster T, Green N: Stage-based interventions for smoking cessation. Co-chrane Database Syst Rev 2010;CD004492.
27. Riemsma RP, Pattenden J, Bridle C, Sowden AJ, Mather L, Watt IS, Walker A: Systematic review of the effectiveness of stage based interventions to promote smoking cessation. BMJ 2003; 326:1175-1177.
28. Bryant J, Bonevski B, Paul C, McElduff P, Attia J: A systematic review and meta-analysis of the effectiveness of behavioural smoking cessation interventions in selected disadvantaged groups. Addiction 2011; 106:1568-1585.
29. Gwaltney CJ, Metrik J, Kahler CW, Shiffman S: Self-efficacy and smoking cessation: a meta-analysis. Psychol Addict Behav 2009; 23: 56-66.
30. Torchalla I, Okoli CT, Bottorff JL, Qu A, Poole N, Greaves L: Smoking cessation programs targeted to women: a systematic review. Women Health 2012; 52:32-54.
31. David SP, Munafò MR, Murphy MF, Walton RT, Johnstone EC: The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob Res 2007; 9:225-231.
32. David SP, Johnstone EC, Murphy MF, Ave-yard P, Guo B, Lerman C, Munafò MR: Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend 2008; 98:77-85.
33. Munafò MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C: Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Bio-markers Prev 2006; 15:398-400.
34. Quaak M, van Schayck CP, Postma DS, Wa-gena EJ, van Schooten FJ: Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction 2012; 107:178-187.
35. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH: The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004; 4:184-192.
36. Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC: Association of the mu-opi-oid receptor gene with smoking cessation. Pharmacogenomics J 2007; 7:353-361.
37. Munafò MR, Johnstone EC, Murphy MF, Aveyard P: Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob Res 2009; 11:404-407.
38. Styn MA, Nukui T, Romkes M, Perkins K, Land SR, Weissfeld JL: The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:254-261.
39. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, Curry SJ, McAfee T: Dopa-mine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005; 5: 21-29.
40. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH: Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22:541-548.
41. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W: Role of functional genetic variation in the dopa-mine D2 receptor (DRD2) in response to bu-propion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacolo-gy 2006; 31:231-242.
42. David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, Evins EA, Shields PG, Lerman C, Niaura R: Bupro-pion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 2007; 9:1251-1257.
43. 108/158 Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Bio-markers Prev 2007; 16:1065-1069.
44. Wilcox CS, Noble EP, Oskooilar N: ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. J Investig Med 2011; 59:1280-1283.
45. Leventhal AM, David SP, Brightman M, Strong D, McGeary JE, Brown RA, Lloyd-Richardson EE, Munafò M, Uhl GR, Niaura R: Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J 2012; 12:86-92.
46. Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P, Niaura R, Lerman C: Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007; 61:111-118.
47. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, Shields PG, Lerman C, Strong D, McCaf-fery J, Niaura R: Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 2007; 9:821-833.
48. David SP, Munafò MR, Murphy MF, Proctor M, Walton RT, Johnstone EC: Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 2008; 8:122-128.
49. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR: Association of cate-chol-O- methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 2005; 15:393-398.
50. 108/158 Met genotype with smoking cessation. Pharmacogenet Genomics 2008; 18:121-128.
51. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, Bergen AW, Swan GE, Tyn-dale RF, Benowitz NL, Lerman C; Pharmaco-genetics of Nicotine Addiction and Treatment Consortium: Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008; 17:2834-2848.
52. Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL: Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol Bio-markers Prev 2009; 18:2608-2612.
53. Spruell T, Colavita G, Donegan T, Egawhary M, Hurley M, Aveyard P, Johnstone EC, Murphy MF, Munafò MR: Association between nicotinic acetylcholine receptor single nucle-otide polymorphisms and smoking cessation. Nicotine Tob Res 2012; 14:993-997.
54. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L: Pharmacogenetic investigation of smoking cessation treatment. Pharmacoge-netics 2002; 12:627-634.
55. Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C: Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation. Neuro-psychopharmacology 2012; 37:1683-1688.
56. Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C: Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine Tob Res 2007; 9:1237-1241.
57. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE: Molecular genetics of nicotine dependence and abstinence: whole genome association using 520, 000 SNPs. BMC Genet 2007; 8:10.
58. Drgon T, Johnson C, Walther D, Albino AP, Rose JE, Uhl GR: Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. Mol Med 2009; 15:268-274.
59. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C: Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65:683-693.
60. Uhl GR, Drgon T, Johnson C, Ramoni MF, Behm FM, Rose JE: Genome-wide association for smoking cessation success in a trial of precessation nicotine replacement. Mol Med 2010; 16:513-526.
61. Heitjan DF, Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C: Identification of phar-macogenetic markers in smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:712-719.
62. Ray R, Mitra N, Baldwin D, Guo M, Patterson F, Heitjan DF, Jepson C, Wileyto EP, Wei J, Payne T, Ma JZ, Li MD, Lerman C: Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology 2010; 35:1374-1382.
63. Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, Tyndale RF, Benowitz NL, Lerman C, Conti DV: Gender-stratified gene and gene-treatment interactions in smoking cessation. Pharmacogenomics J 2012; 12:521-532.
64. Stead LF, Perera R, Bullen C, Mant D, Hart-mann-Boyce J, Cahill K, Lancaster T: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 11:CD000146.
65. Cepeda-Benito A, Reynoso JT, Erath S: Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol 2004; 72:712-722.
66. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P: Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009; 338:b1024.
67. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Pilote L: Pharmacothera-pies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179:135-144.
68. Coleman T, Agboola S, Leonardi-Bee J, Taylor M, McEwen A, McNeill A: Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis. Health Tech-nol Assess 2010; 14:1-152.
69. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, Raftery JP, Aveyard PN, Hyde CJ, Barton PM: The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002; 6:1-245.
70. Hughes JR, Stead LF, Lancaster T: Antide-pressants for smoking cessation. Cochrane Database Syst Rev 2007;CD000031.
71. Gourlay SG, Stead LF, Benowitz NL: Cloni-dine for smoking cessation. Cochrane Database Syst Rev 2004;CD000058.
72. Hughes JR, Stead LF, Lancaster T: Nortripty-line for smoking cessation: a review. Nicotine Tob Res 2005; 7:491-499.
73. Holmes S, Zwar N, Jiménez-Ruiz CA, Ryan PJ, Browning D, Bergmann L, Johnston JA: Bupropion as an aid to smoking cessation: a review of real-life effectiveness. Int J Clin Pract 2004; 58:285-291.
74. Zwar N, Richmond R: Bupropion sustained release. A therapeutic review of Zyban. Aust Fam Physician 2002; 31:443-447.
75. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: CD006103.
76. Zierler-Brown SL, Kyle JA: Oral varenicline for smoking cessation. Ann Pharmacother 2007; 41:95-99.
77. Etter JF: Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006; 166:1553-1559.
78. Lancaster T, Stead LF: Mecamylamine (a nicotine antagonist) for smoking cessation. Co-chrane Database Syst Rev 2000;CD001009.
79. David S, Lancaster T, Stead LF, Evins AE: Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2006;CD003086.
80. Cahill K, Ussher MH: Cannabinoid type 1 receptor antagonists for smoking cessation. Co-chrane Database Syst Rev 2011;CD005353.
81. Lancaster T, Stead LF: Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005;CD001292.
82. Mottillo S, Filion KB, Bélisle P, Joseph L, Gervais A, O'Loughlin J, Paradis G, Pihl R, Pilote L, Rinfret S, Tremblay M, Eisenberg MJ: Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 30:718-730.
83. Stead LF, Lancaster T: Group behaviour therapy programmes for smoking cessation. Co-chrane Database Syst Rev 2005;CD001007.
84. Myung SK, McDonnell DD, Kazinets G, Seo HG, Moskowitz JM: Effects of Web-and computer-based smoking cessation programs: meta-analysis of randomized controlled trials. Arch Intern Med 2009; 169:929-937.
85. Cahill K, Perera R: Competitions and incentives for smoking cessation. Cochrane Database Syst Rev 2011;CD004307.
86. Hutton HE, Wilson LM, Apelberg BJ, Tang EA, Odelola O, Bass EB, Chander G: A systematic review of randomized controlled trials: Web-based interventions for smoking cessation among adolescents, college students, and adults. Nicotine Tob Res 2011; 13: 227-238.
87. Civljak M, Sheikh A, Stead LF, Car J: Internet-based interventions for smoking cessation. Cochrane Database Syst Rev 2010;CD007078.
88. Stead LF, Perera R, Lancaster T: Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2006; 3:CD002850.
89. Stead LF, Perera R, Lancaster T: A systematic review of interventions for smokers who contact quitlines. Tob Control 2007; 16(suppl 1): i3-i8.
90. Tzelepis F, Paul CL, Walsh RA, McElduff P, Knight J: Proactive telephone counseling for smoking cessation: meta-analyses by recruitment channel and methodological quality. J Natl Cancer Inst 2011; 103:922-941.
91. Pan W: Proactive telephone counseling as an adjunct to minimal intervention for smoking cessation: a meta-analysis. Health Educ Res 2006; 21:416-427.
92. Hettema JE, Hendricks PS: Motivational interviewing for smoking cessation: a meta-an-alytic review. J Consult Clin Psychol 2010; 78: 868-884.
93. Heckman CJ, Egleston BL, Hofmann MT: Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analy-sis. Tob Control 2010; 19: 410-416.
94. Bodner ME, Dean E: Advice as a smoking cessation strategy: a systematic review and implications for physical therapists. Physiother Theory Pract 2009; 25:369-407.
95. Mantler T, Irwin JD, Morrow D: Motivational interviewing and smoking behaviors: a critical appraisal and literature review of selected cessation initiatives. Psychol Rep 2012; 110:445-460.
96. de Viron S, Van der Heyden J, Ambrosino E, Arbyn M, Brand A, Van Oyen H: Impact of genetic notification on smoking cessation: systematic review and pooled-analysis. PLoS One 2012; 7:e40230.
97. Smerecnik C, Grispen JE, Quaak M: Effectiveness of testing for genetic susceptibility to smoking-related diseases on smoking cessation outcomes: a systematic review and meta-analysis. Tob Control 2012; 21:347-354.
98. Lancaster T, Stead LF: Self-help interventions for smoking cessation. Cochrane Database Syst Rev 2005;CD001118.
99. Mojica WA, Suttorp MJ, Sherman SE, Morton SC, Roth EA, Maglione MA, Rhodes SL, Shekelle PG: Smoking-cessation interventions by type of provider: a meta-analysis. Am J Prev Med 2004; 26:391-401.
100. Bize R, Burnand B, Mueller Y, Rege WM, Cornuz J: Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2009;CD004705.
101. Bize R, Burnand B, Mueller Y, Cornuz J: Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review. Tob Control 2007; 16:151-156.
102. McClure JB: Are biomarkers a useful aid in smoking cessation? A review and analysis of the literature. Behav Med 2001; 27:37-47.
103. Leeks KD, Hopkins DP, Soler RE, Aten A, Chattopadhyay SK, Task Force on Community Preventive Services: Worksite-based incentives and competitions to reduce tobacco use. A systematic review. Am J Prev Med 2010; 38(suppl 2):S263-S274.
104. Cahill K, Perera R: Quit and Win contests for smoking cessation. Cochrane Database Syst Rev 2008;CD004986.
105. Green JP, Jay Lynn S, Montgomery GH: A meta-analysis of gender, smoking cessation, and hypnosis: a brief communication. Int J Clin Exp Hypn 2006; 54:224-233.
106. Green JP, Lynn SJ, Montgomery GH: Gender-related differences in hypnosis-based treatments for smoking: a follow-up meta-analysis. Am J Clin Hypn 2008; 50:259-271.
107. Tahiri M, Mottillo S, Joseph L, Pilote L, Eisenberg MJ: Alternative smoking cessation aids: a meta-analysis of randomized controlled trials. Am J Med 2012; 125:576-584.
108. White AR, Rampes H, Campbell JL: Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2011;CD000009.
109. Ussher MH, Taylor A, Faulkner G: Exercise interventions for smoking cessation. Co-chrane Database Syst Rev 2012; 1:CD002295.
110. Ussher MH, Taylor AH, West R, McEwen A: Does exercise aid smoking cessation? A systematic review. Addiction 2000; 95:199-208.
111. Hajek P, Stead LF: Aversive smoking for smoking cessation. Cochrane Database Syst Rev 2004;CD000546.
112. Stead LF, Bergson G, Lancaster T: Physician advice for smoking cessation. Cochrane Database Syst Rev 2008;CD000165.
113. Zbikowski SM, Magnusson B, Pockey JR, Tindle HA, Weaver KE: A review of smoking cessation interventions for smokers aged 50 and older. Maturitas 2012; 71:131-141.
114. Rice VH, Stead L: Nursing intervention and smoking cessation: meta-analysis update. Heart Lung 2006; 35:147-163.
115. Rice VH, Stead LF: Nursing interventions for smoking cessation. Cochrane Database Syst Rev 2008;CD001188.
116. Carson KV, Verbiest ME, Crone MR, Brinn MP, Esterman AJ, Assendelft WJ, Smith BJ: Training health professionals in smoking cessation. Cochrane Database Syst Rev 2012; 5:CD000214.
117. Asfar T, Ebbert JO, Klesges RC, Relyea GE: Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav 2011; 36:764-768.
118. Shah SD, Wilken LA, Winkler SR, Lin SJ: Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc (2003) 2008; 48:659-665.
119. Papadakis S, Mcdonald P, Mullen KA, Reid R, Skulsky K, Pipe A: Strategies to increase the delivery of smoking cessation treatments in primary care settings: a systematic review and meta-analysis. Prev Med 2010; 51:199-213.
120. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF: CYP2B6 genotype alters abstinence rates in a bupro-pion smoking cessation trial. Biol Psychiatry 2007; 62:635-641.
121. Park EW, Tudiver F, Schultz JK, Campbell T: Does enhancing partner support and interaction improve smoking cessation? A me-ta-analysis. Ann Fam Med 2004; 2:170-174.
122. Park EW, Schultz JK, Tudiver F, Campbell T, Becker L: Enhancing partner support to improve smoking cessation. Cochrane Database Syst Rev 2012;CD002928.
123. May S, West R: Do social support interventions ('buddy systems') aid smoking cessation? A review. Tob Control 2000; 9:415-422.
124. Cahill K, Moher M, Lancaster T: Workplace interventions for smoking cessation. Co-chrane Database Syst Rev 2008;CD003440.
125. Wilson LM, Avila TE, Chander G, Hutton HE, Odelola OA, Elf JL, Heckman-Stoddard BM, Bass EB, Little EA, Haberl EB, Apelberg BJ: Impact of tobacco control interventions on smoking initiation, cessation, and prevalence: a systematic review. J Environ Public Health 2012; 2012:961724.
126. Bala M, Strzeszynski L, Cahill K: Mass media interventions for smoking cessation in adults. Cochrane Database Syst Rev 2008; CD004704.
127. Niederdeppe J, Kuang X, Crock B, Skelton A: Media campaigns to promote smoking cessation among socioeconomically disad-vantaged populations: what do we know, what do we need to learn, and what should we do now? Soc Sci Med 2008; 67:1343-1355.
128. Hopkins DP, Razi S, Leeks KD, Priya KG, Chattopadhyay SK, Soler RE; Task Force on Community Preventive Services: Smokefree policies to reduce tobacco use. A systematic review. Am J Prev Med 2010; 38(suppl 2): S275-S289.
129. Alegría-Torres JA, Baccarelli A, Bollati V: Epigenetics and lifestyle. Epigenomics 2011; 3:267-277.
130. Parascandola M: Causes, risks, and probabilities: probabilistic concepts of causation in chronic disease epidemiology. Prev Med 2011; 53:232-234.
131. Pianezza ML, Sellers EM, Tyndale RF: Nicotine metabolism defect reduces smoking. Nature 1998; 393:750.
132. Mermelstein R: Ethnicity, gender and risk factors for smoking initiation: an overview. Nicotine Tob Res 1999; 1(suppl 2):S39-S43.
133. Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, Agusti A, Anderson W, Lomas DA, Demeo DL: Cigarette smoking behaviors and time since quitting are associated with differential DNA meth-ylation across the human genome. Hum Mol Genet 2012; 21:3073-3082.
134. Flom JD, Ferris JS, Liao Y, Tehranifar P, Richards CB, Cho YH, Gonzalez K, Santella RM, Terry MB: Prenatal smoke exposure and genomic DNA methylation in a multiethnic birth cohort. Cancer Epidemiol Bio-markers Prev 2011; 20:2518-2523.
135. Munafò MR, Clark TG, Moore LR, Payne E, Walton R, Flint J: Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis. Mol Psychiatry 2003; 8:471-484.
136. Fletcher JM: Why have tobacco control policies stalled? Using genetic moderation to examine policy impacts. PLoS One 2012; 7:e50576.
137. Pechey R, Spiegelhalter D, Marteau TM: Impact of plain packaging of tobacco products on smoking in adults and children: an elici-tation of international experts' estimates. BMC Public Health 2013; 13:18.
138. Hughes JR, Shiffman S, Callas P, Zhang J: A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003; 12:21-27.
139. Perkins KA, Scott J: Sex differences in longterm smoking cessation rates due to nicotine patch. Nicotine Tob Res 2008; 10:1245-1250.
140. Shiffman S, Ferguson SG: Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 2008; 103:557-563.
141. Lindson N, Aveyard P: An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology (Berl) 2011; 214: 579-592.
142. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011; 2: CD006103.
143. Aveyard P, Begh R, Parsons A, West R: Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction 2012; 107:1066-1073.
144. Shahab L, McEwen A: Online support for smoking cessation: a systematic review of the literature. Addiction 2009; 104:1792-1804.
145. Smedslund G, Fisher KJ, Boles SM, Lichtenstein E: The effectiveness of workplace smoking cessation programmes: a meta-analysis of recent studies. Tob Control 2004; 13:197-204.
146. Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P: CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res 2011; 13: 982-988.